论文部分内容阅读
目的探讨CD117在急性白血病中的表达及其临床意义。方法应用CD45/SSC设门,直接荧光标记法,经流式细胞术对73例急性髓系白血病(AML)和47例急性淋巴细胞白血病(ALL)进行CD117的检测。结果对照组、ALL及AML3组CD117的表达阳性率差异有统计学意义(χ2=41.681,P﹤0.01)。AML组CD117的表达阳性率(58.9%)明显高于对照组(0)及ALL组(8.5%)。CD117/CD34的共表达率ALL组明显低于AML组(4.3%vs45.2%,P﹤0.05)。AML组CD117+患者的CR率为60.5%,CD117-患者为76.7%,两者比较差异无统计学意义(P>0.05);而CD117+/CD34+患者的CR率为54.5%,明显低于CD117-/CD34-患者的CR率(88.2%,P﹤0.05)。结论 CD117可作为辅助诊断AML的髓系标志抗原,CD34+/CD117+可作为进一步排除ALL的指标。CD117+/CD34+可能是AML中一类预后不良的特殊亚型,可以作为AML预后判断的指标之一。
Objective To investigate the expression of CD117 in acute leukemia and its clinical significance. Methods CD45 / SSC was used to detect CD117 in 73 cases of acute myeloid leukemia (AML) and 47 cases of acute lymphoblastic leukemia (ALL) by flow cytometry with direct fluorescence labeling. Results The positive rate of CD117 in control group, ALL and AML3 group was significantly different (χ2 = 41.681, P <0.01). The positive rate of CD117 expression in AML group (58.9%) was significantly higher than that in control group (0) and ALL group (8.5%). The co-expression rate of CD117 / CD34 in ALL group was significantly lower than that in AML group (4.3% vs45.2%, P <0.05). The CR rate of CD117 + patients with AML was 60.5% and that of CD117- patients was 76.7% (P> 0.05). The CR rate of CD117 + / CD34 + patients was 54.5%, which was significantly lower than that of CD117- / The CR rate of CD34-patients (88.2%, P <0.05). Conclusion CD117 can be used as a myeloid marker antigen for diagnosis of AML. CD34 + / CD117 + can be used as an indicator to further exclude ALL. CD117 + / CD34 + may be a special subtype of poor prognosis in AML, which can be used as an indicator of prognosis of AML.